NCT05674175View on ClinicalTrials.gov

Co-administration of CART22-65s and huCART19 for B-ALL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

January 15, 2027

Study Completion Date

January 15, 2029

Conditions
B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Interventions
BIOLOGICAL

Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)

CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain

BIOLOGICAL

Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

Stephan Grupp MD PhD

OTHER